Bayer to cut 6,100 jobs globally

Share this article:
Bayer said Friday it plans to eliminate 6,100 jobs as a result of its acquisition of German rival Schering, The Wall Street Journal reported. Bayer said of the job cuts 1,500 will be in Germany, where Schering employed around 7,000 people and where Bayer has around 37,600 employees. On Wednesday, Bayer already said it would cut 950 jobs at Schering’s former Berlin headquarters, which currently has a staff of 6,000 people. A further 160 jobs will be lost at the German Bayer sit in Wuppertal, Germany and 140 more at a former Schering site in Jena, Germany. Bayer is to cut in total 3,150 jobs across Europe, including the job losses in Germany. Additionally, 1,000 job cuts are planned in the US, 750 in Japan and the Asia Pacific region and 1,200 in Latin America and Canada. Of the 6,100 jobs to be eliminated, 2,850 will be administrative positions. About 1,850 production jobs will be cut and 1,400 are to go in research and development.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...